ARVINAS, INC. Investing Cash Flow
ARVINAS, INC. (ARVN) reported Investing Cash Flow of $68.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- ARVINAS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $54.90M, a 57.38% decline year-over-year.
- ARVINAS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $13.70M, a 80.29% decline year-over-year.
- ARVINAS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $145.80M, a 47.42% increase year-over-year.
- ARVINAS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $63.50M, a 25.74% increase year-over-year.
- ARVINAS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $407.60M, a 1074.64% increase from fiscal 2024.
- ARVINAS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $34.70M, a 82.95% decline from fiscal 2023.
- ARVINAS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $203.50M, a 16.19% decline from fiscal 2022.
- ARVINAS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $242.80M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $54.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $68.60M 10-Q · filed 2026-08-04 | $214.40M derived: sum of 3 quarters · filed 2026-08-04 | $277.90M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $13.70M 10-Q · filed 2026-05-11 | $159.50M derived: sum of 2 quarters · filed 2026-05-11 | $223.00M derived: sum of 3 quarters · filed 2026-05-11 | $351.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $145.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $209.30M derived: sum of 2 quarters · filed 2026-02-24 | $338.10M derived: sum of 3 quarters · filed 2026-08-04 | $407.60M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $63.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $192.30M derived: sum of 2 quarters · filed 2026-08-04 | $261.80M 10-Q · filed 2025-11-05 | $360.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $128.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $198.30M 10-Q · filed 2026-08-04 | $297.20M derived: sum of 3 quarters · filed 2026-08-04 | $347.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $69.50M 10-Q · filed 2026-05-11 | $168.40M derived: sum of 2 quarters · filed 2026-05-11 | $218.90M derived: sum of 3 quarters · filed 2026-05-11 | $232.00M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $98.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $149.40M derived: sum of 2 quarters · filed 2026-02-24 | $162.50M derived: sum of 3 quarters · filed 2026-02-24 | $34.70M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $50.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $63.60M derived: sum of 2 quarters · filed 2025-11-05 | -$64.20M 10-Q · filed 2025-11-05 | -$117.90M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $13.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$114.70M 10-Q · filed 2025-08-06 | -$168.40M derived: sum of 3 quarters · filed 2026-02-24 | -$98.40M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$127.80M 10-Q · filed 2025-05-01 | -$181.50M derived: sum of 2 quarters · filed 2026-02-24 | -$111.50M derived: sum of 3 quarters · filed 2026-02-24 | -$62.90M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | -$53.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.30M derived: sum of 2 quarters · filed 2026-02-24 | $64.90M derived: sum of 3 quarters · filed 2026-02-24 | $203.50M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $70.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $118.60M derived: sum of 2 quarters · filed 2024-10-30 | $257.20M 10-Q · filed 2024-10-30 | $276.60M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $48.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $187.20M 10-Q · filed 2024-07-30 | $206.60M derived: sum of 3 quarters · filed 2025-02-11 | $312.40M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $138.60M 10-Q · filed 2024-05-07 | $158.00M derived: sum of 2 quarters · filed 2025-02-11 | $263.80M derived: sum of 3 quarters · filed 2025-02-11 | $372.80M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $19.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $125.20M derived: sum of 2 quarters · filed 2025-02-11 | $234.20M derived: sum of 3 quarters · filed 2025-02-11 | $242.80M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $105.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $214.80M derived: sum of 2 quarters · filed 2023-11-07 | $223.40M 10-Q · filed 2023-11-07 | $107.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $109.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $117.60M 10-Q · filed 2023-08-08 | $2.00M derived: sum of 3 quarters · filed 2024-02-27 | -$739.10M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $8.60M 10-Q · filed 2023-05-05 | -$107.00M derived: sum of 2 quarters · filed 2024-02-27 | -$848.10M derived: sum of 3 quarters · filed 2024-02-27 | -$1.10B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$115.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$856.70M derived: sum of 2 quarters · filed 2024-02-27 | -$1.11B derived: sum of 3 quarters · filed 2024-02-27 | -$1.31B 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | -$741.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$990.20M derived: sum of 2 quarters · filed 2022-11-09 | -$1.20B 10-Q · filed 2022-11-09 | -$1.20B 10-Q · filed 2021-11-03 | -$1.14B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-06-30 | -$249.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$456.90M 10-Q · filed 2022-08-04 | -$456.87M 10-Q · filed 2021-08-05 | -$399.99M derived: sum of 3 quarters · filed 2023-02-23 | -$340.70M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-03-31 | -$207.80M 10-Q · filed 2022-05-05 | -$207.82M 10-Q · filed 2021-05-04 | -$150.89M derived: sum of 2 quarters · filed 2023-02-23 | -$91.60M derived: sum of 3 quarters · filed 2023-02-23 | -$85.99M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $56.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $116.20M derived: sum of 2 quarters · filed 2023-02-23 | $121.81M derived: sum of 3 quarters · filed 2023-02-23 | $164.30M 10-K · filed 2023-02-23 | $164.25M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $59.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $64.89M derived: sum of 2 quarters · filed 2021-11-03 | $107.39M 10-Q · filed 2021-11-03 | $11.96M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $5.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $48.10M 10-Q · filed 2021-08-05 | -$47.33M derived: sum of 3 quarters · filed 2022-02-28 | -$79.14M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $42.49M 10-Q · filed 2021-05-04 | -$52.94M derived: sum of 2 quarters · filed 2022-02-28 | -$84.75M derived: sum of 3 quarters · filed 2022-02-28 | -$88.98M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | -$95.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$127.25M derived: sum of 2 quarters · filed 2022-02-28 | -$131.47M derived: sum of 3 quarters · filed 2022-02-28 | -$93.10M 10-K · filed 2022-02-28 | -$93.10M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | -$31.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$36.04M derived: sum of 2 quarters · filed 2020-11-05 | $2.33M 10-Q · filed 2020-11-05 | -$99.53M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | -$4.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $34.15M 10-Q · filed 2020-08-04 | -$67.72M derived: sum of 3 quarters · filed 2021-03-01 | -$55.92M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $38.37M 10-Q · filed 2020-04-28 | -$63.49M derived: sum of 2 quarters · filed 2021-03-01 | -$51.69M derived: sum of 3 quarters · filed 2021-03-01 | -$96.95M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$101.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$90.06M derived: sum of 2 quarters · filed 2021-03-01 | -$135.33M derived: sum of 3 quarters · filed 2021-03-01 | -$179.67M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $11.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$33.47M derived: sum of 2 quarters · filed 2019-11-04 | -$77.80M 10-Q · filed 2019-11-04 | -$77.46M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | -$45.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$89.60M 10-Q · filed 2019-08-05 | -$89.26M derived: sum of 3 quarters · filed 2019-08-05 | |||||
| 2018-03-31 | -$44.34M 10-Q · filed 2019-05-09 | -$44.00M derived: sum of 2 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $339.54K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $20.87M 10-K · filed 2019-03-26 | ||||||
| 2017-09-30 | $20.53M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |